GlassScriptPhysician profile
Patricia E Smith
NPI 1801304423
$3,941.95
in general payments reported to CMS, 2019-2025
19 companies · $396 in 2025
The $396 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $329 · 2022: $1,378 · 2023: $1,839 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,234.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $818.27 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $689.91 | 2022-2023 | |
| Alkermes, INC. | $639.79 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $601.66 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $222.94 | 2021-2023 | Ingrezza |
| Corium, LLC | $208.56 | 2022-2023 | Azstarys |
| Sunovion Pharmaceuticals INC. | $173.83 | 2021-2022 | |
| Axsome Therapeutics, INC. | $171.85 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $117.98 | 2021-2023 | Spravato, Invega Trinza, Invega |
| Lundbeck LLC | $68.43 | 2022-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $42.88 | 2021-2023 | Uzedy |
| Vanda Pharmaceuticals INC. | $39.20 | 2023 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $34.67 | 2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $25.79 | 2022 | |
| Amarin Pharma, INC. | $19.22 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $18.77 | 2025 | |
| Supernus Pharmaceuticals, INC. | $17.03 | 2023 | Qelbree |
| Insulet Corporation | $16.49 | 2021 | |
| Adlon Therapeutics L.P. | $14.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.